CalciMedica Beats Quarterly Loss Estimate by $1.03 per Share

CalciMedica reported ($0.24) earnings per share for its latest quarter on Tuesday, beating the consensus analyst estimate of ($1.27) by $1.03, according to FiscalAI. For a clinical-stage biopharmaceutical company with no marketed product, the size of that gap matters less as a profitability signal than as a check on how analysts model the cash burn.

The market shrugged. CALC stock fell $0.05, or 3.3 percent, in midday trading on Tuesday, reaching $1.47. Only 1,439 shares changed hands against an average daily volume of 175,517 — a session so thin that price moves carry little information.

What do the balance sheet numbers show?

The figures point to a small company under visible strain. CalciMedica carries a market capitalization of $10.01 million, with a price-to-earnings ratio of -0.22 and a beta of 0.84. Key metrics:

• Debt-to-equity ratio: 1.67
• Quick ratio: 5.58
• Current ratio: 5.58
• 50-day simple moving average: $1.60
• 200-day simple moving average: $3.50

The 1-year trading range tells the harder story. The stock has touched a low of $1.00 and a high of $36.00 — a collapse of more than 95 percent from peak to trough. Liquidity ratios near 5.58 remain strong, meaning short-term obligations are well covered, but the moving averages confirm a sustained downtrend rather than a one-off shock. In plain words: the balance sheet buys time, the share price shows how much the market values it.

How have analysts reacted?

Research firms have split sharply. Recent actions include:

• Guggenheim began coverage with a "buy" rating on Thursday, August 20.
• Wall Street Zen cut the stock from "sell" to "strong sell" on Saturday, September 12.
• HC Wainwright reiterated a "neutral" rating on Wednesday, July 29.
• Weiss Ratings upgraded from "sell (e+)" to "sell (d-)" on Thursday, August 27.
• UBS Group reissued a "neutral" rating on Thursday, August 13.

Across the coverage universe, two analysts rate the stock a Buy, two assign a Hold, and one has a Sell rating. MarketBeat calculates an average rating of "Hold" with an average price target of $50.00 — a figure that sits roughly 34 times above the current share price and reflects outlier targets rather than near-term consensus on value.

The takeaway: sell-side opinion spans the full spectrum, from strong sell to buy, an unusually wide spread that signals genuine disagreement about the company's prospects.

What is the company actually building?

CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory and immune-mediated diseases. Its research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

The lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor under evaluation as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.

For finance teams watching the name, the investment case rests on clinical outcomes for zelnecirnon, not on quarterly EPS arithmetic. With $10.01 million in market value, a stock at $1.47, and coverage that ranges from strong sell to buy, CalciMedica remains a binary development story where the balance sheet's liquidity cushions a valuation the market has already repriced downward.